Inclusion and exclusion criteria
NSCLC
SECONDARY, NSCLC
The titles and abstracts were examined. Only phase III RCTs in metastatic NSCLC that reported QoL results and at least one survival outcome between OS and PFS were considered eligible for further analysis. The following RCTs were excluded from the analysis: (1) trials testing surgery and/or radiotherapy; (2) trials non-including QoL among study endpoints; (3) trials not reporting QoL results in primary or secondary publications; (4) trials not reporting results of at least one survival outcome between PFS and OS; (5) trials evaluating multiple schedules of administration of the same drug; (6) trials of supportive care or behavioral approaches; (7) not phase III RCTs; (8) trials in locally advanced, neo-adjuvant, or adjuvant settings; (9) study protocols; (10) subgroup or post hoc analysis of previously published trials; (11) brief reports or case studies; (12) research of screening methodologies; and (13) pooled analysis of multiple trials. The remaining full texts were downloaded for further analysis.